Gubra AS
€48.2
39
-€0.12-0.25% Thursday 15:28
Statistics
Day High
47.84
Day Low
47.84
52W High
75.2
52W Low
43.96
Volume
-
Avg. Volume
-
Mkt Cap
788.07M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Dividends
0%Dividend Yield
Jul 25
€8.2
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A
Earnings
27FebExpected
Expected EPS
-0.007967068200000002
Actual EPS
-0.5842516680000001
Financials
64.12%Profit Margin
Profitable706.45MRevenue
452.96MNet Income
People Also Follow
This list is based on the watchlists of people on Stock Events who follow PI3.F. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap217.54B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Sanofi
SNY
Mkt Cap124.45B
Astrazeneca
AZN
Mkt Cap256.58B
Merck
MRK
Mkt Cap214.76B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Pfizer
PFE
Mkt Cap140.15B
Roche
RHHBY
Mkt Cap258.9B
Takeda Pharmaceutical
TAK
Mkt Cap42.62B
About
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, pharmacokinetics, and 2D and 3D histology with artificial intelligence pathology. The company has partnership and collaboration with Boehringer Ingelheim for the treatment of obesity; Hemab ApS to treat bleeding disorders; and Amylyx Pharmaceuticals, Inc. to develop a novel long-acting GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseases. Gubra A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Show more...
CEO
Mr. Jacob Jelsing
Employees
180
Country
Denmark
ISIN
DK0062266474
WKN
000A3D9NV
Listings
0 Comments
Share your thoughts
FAQ
What is Gubra AS stock price today?▼
The current price of PI3.F is €48.2 EUR — it has decreased by -0.25% in the past 24 hours. Watch Gubra AS stock price performance more closely on the chart.
What is Gubra AS stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Gubra AS stocks are traded under the ticker PI3.F.
Is Gubra AS stock price growing?▼
PI3.F stock has risen by +0.42% compared to the previous week, the month change is a -8.37% fall, over the last year Gubra AS has showed a -4.74% decrease.
What is Gubra AS market cap?▼
Today Gubra AS has the market capitalization of 788.07M
When is the next Gubra AS earnings date?▼
Gubra AS is going to release the next earnings report on August 20, 2026.
What were Gubra AS earnings last quarter?▼
PI3.F earnings for the last quarter are -0.58 EUR per share, whereas the estimation was -0.01 EUR resulting in a -7,233.33% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Gubra AS revenue for the last year?▼
Gubra AS revenue for the last year amounts to 706.45M EUR.
What is Gubra AS net income for the last year?▼
PI3.F net income for the last year is 452.96M EUR.
Does Gubra AS pay dividends?▼
Yes, PI3.F dividends are paid en. The last dividend per share was 8.2 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Gubra AS have?▼
As of April 04, 2026, the company has 180 employees.
In which sector is Gubra AS located?▼
Gubra AS operates in the Healthcare sector.
When did Gubra AS complete a stock split?▼
Gubra AS has not had any recent stock splits.
Where is Gubra AS headquartered?▼
Gubra AS is headquartered in Horsholm, Denmark.